J Clin Med:单纯的低促性腺素性功能减退症患者的生活质量和性满意度降低

2021-07-18 AlexYang MedSci原创

单纯的低促性腺素性功能减退症(IHH),又称单纯性促性腺激素释放激素(GnRH)缺乏症或特发性促性腺激素不足症,是一种下丘脑-垂体轴的发育障碍,引起GnRH缺乏。下丘脑-垂体-性腺轴缺乏青春期激活,会

单纯的低促性腺素性功能减退症(IHH),又称单纯性促性腺激素释放激素(GnRH)缺乏症或特发性促性腺激素不足症,是一种下丘脑-垂体轴的发育障碍,引起GnRH缺乏。下丘脑-垂体-性腺轴缺乏青春期激活,会导致青春期缺失或停止,并导致不育。

单纯的低促性腺素性功能减退症是一种以青春期和生育能力受损为特征的遗传性疾病。IHH会显著影响患者的健康相关生活质量(HRQoL)、性满意度(SS)和情绪。

近期,有研究人员调查了IHH患者的生活质量和性满意度情况

研究包括了132名IHH受试者(89名男性和43名女性)和132名性别和年龄匹配的对照。在网上调查中使用Zung抑郁自评量表(SDS)、HRQoL的15D工具(15D)、性满意度问卷(SSQ)和5项国际勃起功能指数(IIEF-5)评估了HRQoL、抑郁症状、勃起功能障碍(ED)和SS情况。

结果发现,IHH组与对照组相比,QoL和SS都明显较低。与对照组相比,患者的ED(53.2% vs. 33%,P=0.008)和抑郁症状(45.00±17.00 vs. 32.00±12.00,P<0.001)比例很高。IHH诊断时患者的年龄与他们的15D总分成反比。出现了令人震惊的不依从率(51.6%)。另外,研究人员在接受激素替代治疗(HRT)的患者和未接受治疗的患者中,没有发现任何量表中的得分存在差异。

IHH患者和对照的评分情况

综上所述,尽管有HRT,在IHH患者中观察到的HRQoL、SS、ED和抑郁症水平结果令人震惊。IHH的晚期诊断可能对HRQoL有特别的负面影响。应更加关注IHH患者的HRT依从性和HRQoL的各方面

原始出处:

Małgorzata Kałużna, Pola Kompf, Michał Rabijewski et al. Reduced Quality of Life and Sexual Satisfaction in Isolated Hypogonadotropic Hypogonadism. J Clin Med. Jun 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1945567, encodeId=37c3194556ebb, content=<a href='/topic/show?id=1a885265349' target=_blank style='color:#2F92EE;'>#性功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52653, encryptionId=1a885265349, topicName=性功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Mon Nov 01 18:32:52 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988165, encodeId=5ee4198816566, content=<a href='/topic/show?id=10195268240' target=_blank style='color:#2F92EE;'>#性满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52682, encryptionId=10195268240, topicName=性满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed May 18 21:32:52 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478707, encodeId=dba714e870768, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611156, encodeId=2c051611156af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1945567, encodeId=37c3194556ebb, content=<a href='/topic/show?id=1a885265349' target=_blank style='color:#2F92EE;'>#性功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52653, encryptionId=1a885265349, topicName=性功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Mon Nov 01 18:32:52 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988165, encodeId=5ee4198816566, content=<a href='/topic/show?id=10195268240' target=_blank style='color:#2F92EE;'>#性满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52682, encryptionId=10195268240, topicName=性满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed May 18 21:32:52 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478707, encodeId=dba714e870768, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611156, encodeId=2c051611156af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1945567, encodeId=37c3194556ebb, content=<a href='/topic/show?id=1a885265349' target=_blank style='color:#2F92EE;'>#性功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52653, encryptionId=1a885265349, topicName=性功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Mon Nov 01 18:32:52 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988165, encodeId=5ee4198816566, content=<a href='/topic/show?id=10195268240' target=_blank style='color:#2F92EE;'>#性满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52682, encryptionId=10195268240, topicName=性满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed May 18 21:32:52 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478707, encodeId=dba714e870768, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611156, encodeId=2c051611156af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1945567, encodeId=37c3194556ebb, content=<a href='/topic/show?id=1a885265349' target=_blank style='color:#2F92EE;'>#性功能减退症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52653, encryptionId=1a885265349, topicName=性功能减退症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0041445, createdName=TZF0804, createdTime=Mon Nov 01 18:32:52 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988165, encodeId=5ee4198816566, content=<a href='/topic/show?id=10195268240' target=_blank style='color:#2F92EE;'>#性满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52682, encryptionId=10195268240, topicName=性满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Wed May 18 21:32:52 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478707, encodeId=dba714e870768, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611156, encodeId=2c051611156af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jul 20 12:32:52 CST 2021, time=2021-07-20, status=1, ipAttribution=)]

相关资讯

Lancet oncol:结肠癌患者手术治疗后的接受不同医生主导的护理的生活质量

结肠癌患者手术治疗后的第一年内,全科医生主导的护理或可替代外科医生指导的护理

Gastric Cancer:晚期胃癌中二线化疗中早期肿瘤应答和生活质量的关系:ABSOLUTE研究的更新

晚期胃癌二线应用紫杉类化疗,早期的肿瘤退缩跟生活质量的维持有关。

Lancet oncol:阿托珠单抗联合贝伐单抗可显著改善晚期肝癌患者报告的生活质量

与索拉非尼相比,采用阿托珠单抗联合贝伐单抗治疗的患者报告的生活质量、功能和疾病症状方面获得了具有临床意义的益处

Ear Nose Throat J:后鼻神经冷冻消融术对慢性鼻炎患者的症状和特定疾病的生活质量的影响

慢性鼻炎在美国影响了8000多万人,通过流行研究的推断,全世界受影响的人口大约有4.5亿。受这种疾病过程影响的人口规模使得可查的其对经济影响。在21世纪初,仅过敏性鼻炎(AR)就造成了超过30亿美元的

那些接受减重代谢手术的后来怎么样了?

减重代谢手术(MBS)是严重肥胖症的标准治疗方案。

Eur Arch Otorhinolaryngol:人工耳蜗植入前后深度语后听力损失成人的健康相关生活质量

对于后天获得性耳聋的人来说,完成普通的生活任务和充分参与社会活动是很困难的。深度听力损失减少了人际交往,从而导致排斥社会和相关的心理后果,如抑郁症。为了减少成人语后深度听力损失的影响,通常使用人工耳蜗